Para peneliti luncurkan proyek BRIDGE mengenai kanker payudara agresif

Para ilmuwan dari ITQB NOVA dan Institut Onkologi Portugal telah memulai proyek BRIDGE untuk mengungkap bagaimana kanker payudara agresif menghindari sistem kekebalan tubuh. Inisiatif ini mencari biomarker untuk prediksi perkembangan penyakit yang lebih baik serta perawatan yang dipersonalisasi. Didanai hingga €75.000, upaya dua tahun ini menggunakan sampel pasien untuk memvalidasi temuan laboratorium.

Proyek BRIDGE, singkatan dari Biomarker Research Integrating Data of Glyco-Immune Signatures and Clinical Evidence in Breast Cancer, menargetkan lingkungan mikro tumor di mana sel kanker berinteraksi dengan sel kekebalan tubuh. Para peneliti bertujuan untuk mengidentifikasi molekul kecil pada permukaan sel yang memungkinkan tumor menekan deteksi kekebalan, yang menyebabkan pertumbuhan yang tidak terkendali. Hal ini didasarkan pada penemuan sebelumnya mengenai komunikasi tumor-imun, yang kini diuji dengan sampel pasien nyata dari IPOFG.

Artikel Terkait

Photorealistic illustration of long-term breast cancer vaccine trial survivors linked to CD27 immune memory, with lab research elements.
Gambar dihasilkan oleh AI

Decades after a small breast cancer vaccine trial, researchers link lasting immune memory to CD27

Dilaporkan oleh AI Gambar dihasilkan oleh AI Fakta terverifikasi

More than 20 years after a small Duke-led clinical trial tested an experimental breast cancer vaccine, Duke Health says all participating women are still alive—an outcome researchers describe as unusual for metastatic disease. Follow-up analyses found long-lived immune cells marked by CD27, and mouse experiments suggest that stimulating CD27 can boost vaccine-driven tumor control.

Researchers at the University of Geneva have developed MangroveGS, an AI model that predicts cancer metastasis risk with nearly 80% accuracy. The tool analyzes gene expression patterns in tumor cells, initially from colon cancer, and applies to other types like breast and lung. Published in Cell Reports, it aims to enable more personalized treatments.

Dilaporkan oleh AI

Scientists at KAIST in South Korea have developed a novel therapy that transforms a tumor's own immune cells into potent cancer fighters directly inside the body. By injecting lipid nanoparticles into tumors, the treatment reprograms macrophages to produce cancer-recognizing proteins, overcoming barriers in solid tumor treatment. Early animal studies show promising reductions in tumor growth.

Researchers tested a redesigned CD40 agonist antibody, 2141-V11, by injecting it directly into tumors of 12 patients with metastatic cancers. Six patients saw tumor shrinkage, with two achieving complete remission, including effects on untreated tumors elsewhere in the body. The trial reported only mild side effects, unlike prior CD40 therapies.

Dilaporkan oleh AI Fakta terverifikasi

Researchers at the Max Planck Institute of Immunobiology and Epigenetics (MPI-IE) in Freiburg report that a key assumption behind widely used BET-inhibitor drug strategies may be wrong: the BET proteins BRD2 and BRD4 are not interchangeable. The team says BRD2 helps prepare genes for activation while BRD4 acts later to enable productive transcription—differences that could contribute to the modest and unpredictable results seen with drugs that inhibit BET proteins broadly.

Researchers at Memorial Sloan Kettering Cancer Center report that colorectal tumors can contain two major subtypes of regulatory T cells with opposing effects—one associated with restraining tumor growth and another linked to suppressing anti-tumor immunity. The work, published in Immunity, helps explain why higher overall levels of these immune cells have been tied to better outcomes in colorectal cancer and suggests a potential strategy for more selective Treg-targeted therapies.

Dilaporkan oleh AI

A repurposed breast cancer drug called MDL-001 has shown promise in lab and animal studies against a range of viruses, including flu, covid-19, RSV and norovirus. Developed by California-based Model Medicines using AI, the pill targets a conserved enzyme domain in viruses. A clinical trial is planned for early next year.

 

 

 

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak